| Date | Title | Description | Source |
| 25.04.2024 | PRISM BioLab, enters into a Joint Research and Licensing Agr... | PRISM BioLab will utilize PepMetics®, innovative small molecules that mimic three-dimensional struct... | en.prnasia... |
| 24.04.2024 | Leqembi® revenue totaled JPY 2.83 billion in the first quart... | Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
Wed, Apr 24, 2024 12:45 CET Repo... | news.cisio... |
| 20.04.2024 | BioArctic and Eisai sign research evaluation agreement regar... | BioArctic and Eisai sign research evaluation agreement regarding BAN2802
Sat, Apr 20, 2024 09:40 CET... | news.cisio... |
| 18.04.2024 | BioArctic publishes the Annual Report for 2023 | BioArctic publishes the Annual Report for 2023
Thu, Apr 18, 2024 08:00 CET Report this content
Stock... | news.cisio... |
| 10.04.2024 | BioArctic’s focus on Sustainable Innovation qualifies compan... | BioArctic’s focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Na... | news.cisio... |
| 01.04.2024 | Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintena... | Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Al... | news.cisio... |
| 22.03.2024 | Lecanemab deliberations at the CHMP regarding the Marketing ... | Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have... | news.cisio... |
| 19.03.2024 | Professor Lars Lannfelt, awarded Fondation Recherche Alzheim... | Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer’s European Grand Prix for his contrib... | news.cisio... |
| 11.03.2024 | New data on lecanemab presented at the 2024 AD/PD™ congress... | New data on lecanemab presented at the 2024 AD/PD™ congress
Mon, Mar 11, 2024 08:00 CET Report this ... | news.cisio... |
| 08.03.2024 | FDA delays action on Lilly's Alzheimer's drug | The Food and Drug Administration is asking outside advisors to review the safety and efficacy of an ... | axios.com/... |
| 07.03.2024 | HAPPY WOMAN Executive Committee/Eisai Co., Ltd. Consumer hhc... | HAPPY WOMAN Executive Committee/Eisai Co., Ltd. Consumer hhc Division [Gender equality issues to con... | re-how.net... |
| 07.03.2024 | BioArctic’s partner Eisai presents updated sales simulation ... | BioArctic’s partner Eisai presents updated sales simulation for Leqembi® at its annual press confere... | news.cisio... |
| 06.03.2024 | HAPPY WOMAN Executive Committee International Women’s Day Se... | [HAPPY WOMAN Executive Committee] [International Women’s Day Seminar] Mama Ogi will also be on stage... | re-how.net... |
| 04.03.2024 | Biopharmaceutical Innovations Lead the Way in Migraine Drugs... | Migraine is a clinical condition associated with painful headaches and other symptoms such as nausea... | einpresswi... |
| 06.02.2024 | Sales of Leqembi® totaled 1.1 billion yen in the fourth quar... | Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023
Tue, Feb 06, 2024 04:36 CET Rep... | news.cisio... |
| 09.01.2024 | Leqembi® approved for the treatment of Alzheimer’s disease i... | Leqembi® approved for the treatment of Alzheimer’s disease in China
Tue, Jan 09, 2024 09:30 CET Repo... | news.cisio... |
| 07.11.2023 | Your morning biotech news roundup | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech ne... | statnews.c... |
| 20.10.2023 | Teddi Mellencamp Gets Naked for Melanoma Awareness Month | WASHINGTON (PRWEB) May 01, 2023 -- The Melanoma Research Foundation (MRF) is pleased to announce the... | prweb.com/... |
| 16.10.2023 | New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD s... | New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be ... | news.cisio... |
| 19.07.2023 | Eisai Presents Latest Analysis of Lecanemab’s Effect on Biom... | /EIN News/ -- Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two... | einpresswi... |
| 07.07.2023 | FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb... | /EIN News/ -- The first and only approved treatment shown to reduce the rate of disease progression ... | einpresswi... |
| 16.06.2023 | The FDA needs a risk evaluation and mitigation strategy for ... | Over the past several months, my conversations with colleagues in the Alzheimer’s field have feature... | statnews.c... |
| 09.06.2023 | FDA Advisory Committee Votes Unanimously to Confirm the Clin... | /EIN News/ -- Peripheral and Central Nervous System Drugs Advisory Committee voted based on data fro... | einpresswi... |
| 17.05.2023 | Societal value of lecanemab in Japan published in Neurology ... | Societal value of lecanemab in Japan published in Neurology and Therapy
Wed, May 17, 2023 01:30 CET ... | news.cisio... |
| 08.05.2023 | BLISS BIOPHARMACEUTICAL ENTERS INTO A CLINICAL TRIAL COLLABO... | HANGZHOU, China, May 8, 2023 /PRNewswire/ -- Bliss Biopharmaceutical (Hangzhou) Co., Ltd, ("Bli... | en.prnasia... |
| 01.05.2023 | Teddi Mellencamp Gets Naked for Melanoma Awareness Month | WASHINGTON (PRWEB) May 01, 2023
The Melanoma Research Foundation (MRF) is pleased to announce the la... | prweb.com/... |
| 03.04.2023 | New lecanemab-data presented at the AD/PD™ 2023 conference | New lecanemab-data presented at the AD/PD™ 2023 conference
Mon, Apr 03, 2023 08:00 CET Report this c... | news.cisio... |
| 31.03.2023 | Additional Detailed Analyses From Phase 2 Study 201 of Lecan... | TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo,... | einpresswi... |
| 31.03.2023 | EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN... | TOKYO and CAMBRIDGE, Mass., March 30, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO... | einpresswi... |
| 31.03.2023 | Eisai publishes additional detailed analyses from lecanemab ... | Eisai publishes additional detailed analyses from lecanemab phase 2b study
Fri, Mar 31, 2023 08:00 C... | news.cisio... |
| 30.03.2023 | Additional Detailed Analyses From Phase 2 Study 201 of Lecan... | /EIN News/ -- TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headqu... | einpresswi... |
| 23.03.2023 | EISAI TO PRESENT NEW LECANEMAB DATA, INCLUDING RESEARCH EVAL... | Presentations Explore ARIA with the Use of Antiplatelets or Anticoagulants and Isolated ARIA-H in Pa... | einpresswi... |
| 20.03.2023 | EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CL... | TOKYO, March 19, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "... | einpresswi... |
| 20.03.2023 | Eisai publishes societal value of lecanemab using phase 3 Cl... | Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology... | news.cisio... |
| 06.03.2023 | FDA Accepts Eisai's Filing of a Supplemental Biologics Licen... | Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accele... | einpresswi... |
| 07.01.2023 | Eisai Submits Supplemental Biologics License Application to ... | Submission for traditional approval follows FDA accelerated approval of LEQEMBI on the same day, and... | einpresswi... |
| 06.01.2023 | FDA approves LEQEMBI™ (lecanemab-irmb) under the Accelerated... | FDA approves LEQEMBI™ (lecanemab-irmb) under the Accelerated Approval pathway for the treatment of A... | news.cisio... |
| 23.12.2022 | BioArctic’s partner Eisai initiates BLA submission of data f... | BioArctic’s partner Eisai initiates BLA submission of data for lecanemab in China
Fri, Dec 23, 2022 ... | news.cisio... |
| 23.12.2022 | BioArctic’s partner Eisai publishes statement relating to ar... | BioArctic’s partner Eisai publishes statement relating to article on lecanemab in Scienceinsider
Fri... | news.cisio... |
| 23.12.2022 | EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHIN... | TOKYO and CAMBRIDGE, Mass., Dec. 22, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO:... | einpresswi... |
| 20.12.2022 | Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (pera... | TOKYO, Dec 20, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an a... | einpresswi... |
| 15.12.2022 | Eisai and Washington University School of Medicine in St. Lo... | TOKYO, Dec 15, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai and Washington Uni... | einpresswi... |
| 30.11.2022 | BioArctic’s partner Eisai presents results of lecanemab Phas... | BioArctic’s partner Eisai presents results of lecanemab Phase 3 confirmatory Clarity AD study for Ea... | news.cisio... |
| 29.11.2022 | Second Death in Trial of Experimental Alzheimer Drug Raising... | TUESDAY, Nov. 29, 2022 (HealthDay News) -- Two people have now died from brain hemorrhages that may ... | salamancap... |
| 29.11.2022 | Second Death in Trial of Experimental Alzheimer's Drug Is Ra... | TUESDAY, Nov. 29, 2022 (HealthDay News) -- Two people have now died from brain hemorrhages that may ... | salamancap... |
| 21.11.2022 | Results from lecanemab confirmatory phase 3 Clarity AD study... | Results from lecanemab confirmatory phase 3 Clarity AD study to be presented at 15th Clinical Trials... | news.cisio... |
| 21.11.2022 | EISAI TO PRESENT FULL FINDINGS FROM LECANEMAB CONFIRMATORY P... | TOKYO, Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "E... | einpresswi... |
| 16.11.2022 | Metoject Subcutaneous Injection Syringe (Methotrexate) Launc... | TOKYO, Nov 16, 2022 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of m... | einpresswi... |
| 13.10.2022 | Manufacturing roundup: Lonza to manufacture two new ... | Manufacturing giant Lonza can add more FDA-approved therapies to its repertoire.
The comp... | endpts.com... |
| 10.10.2022 | Actinogen Medical Limited (ACW) announces large Xanamem® the... | Clinical Dementia Rating Scale - Sum of Boxes effect of 0.6 to 0.8 points observed in patients with ... | en.prnasia... |
| 04.10.2022 | Eisai Completes Construction of Its New Injection/Research B... | To Strengthen its Research and Development Function for Injectable Drug Formulations
TOKYO, Oct 4, 2... | einpresswi... |
| 02.10.2022 | Первый полёт электрической «Алисы» и как закалялась ARM. Тех... | Отдел новостей 2 октября 2022, 23:41 Первый полёт электрической «Алисы» и как закалялась ARM. Техдай... | dev.by/new... |
| 28.09.2022 | New Alzheimer's drug slows cognitive decline, clinical trial... | Eisai, one of the companies behind the drug, said it hoped to hand the trial data over to the Food a... | businessin... |
| 22.03.2022 | Biogen, Eisai unveil new data on lecanemab, but questions li... | Eisai and Biogen have released more data on lecanemab, another anti-Alzheimer’s drug in the partners... | endpts.com... |
| 14.02.2022 | Roivant Sciences launches Hemavant to chase BMS in anemia fr... | Roivant Sciences, a company that acquires overlooked or shelved drug assets from large pharmaceutica... | medcitynew... |
| 03.02.2022 | Eisai : FY 2021 (Ended March 31, 2022) Third Quarter Financi... | Securities Code: 4523
FY 2021 (Ending March 31, 2022)
Third Quarter Financial Results
Reference Data... | marketscre... |
| 03.02.2022 | Eisai : Reference Data | Securities Code: 4523
FY 2021 (Ending March 31, 2022)
Third Quarter Financial Results
Reference Data... | marketscre... |
| 01.02.2022 | EISAI : RECEIVES THE TOKYO GOVERNOR PRIZE FOR CORPORATE GOVE... | For Print
February 1, 2022
Full text
News release searchSearch
Attachments
Original Link
Original Do... | marketscre... |
| 28.01.2022 | EISAI : ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIV... | For Print
January 28, 2022
Full text
News release searchSearch
Attachments
Original Link
Original Do... | marketscre... |
| 20.12.2021 | Eisai : BIOGEN ANNOUNCES REDUCED PRICE FOR ADUHELM® TO IMPRO... | For Print
December 20, 2021
Full text
News release searchSearch
Attachments
Original Link
Original D... | marketscre... |
| 16.12.2021 | Update on the Phase 4 Confirmatory Study of ADUHELM® | CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (... | marketscre... |
| 30.11.2021 | Eisai and FCNT Enter Into Business Alliance Aiming to Suppor... | TOKYO, Nov 30, 2021 - (JCN Newswire) - - Eisai Co., Ltd. and FCNT LIMITED announced today that both ... | marketscre... |
| 19.11.2021 | EISAI : SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ... | For Print
November 19, 2021
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"... | marketscre... |
| 18.11.2021 | EISAI : RECEIVES THE “MOST LIKED!” IR AWARD AT THE 2021 IR A... | For Print
November 18, 2021
Full text
News release searchSearch
Attachments
Original Link
Original D... | marketscre... |
| 12.11.2021 | New Phase 3 Data Show Positive Correlation Between ADUHELM™ ... | In a pre-specified analysis, ADUHELM significantly lowered plasma p-tau181, a biomarker of the hallm... | marketscre... |
| 11.11.2021 | Eisai Presents Late-Breaker Updates on Lecanemab Clinical, B... | TOKYO, Nov 11, 2021 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. announced today results of ... | marketscre... |
| 10.11.2021 | Eisai Presents Late-Breaker Updates on Lecanemab Clinical, B... | TOKYO and CAMBRIDGE, Mass, Nov. 10, 2021 - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &... | marketscre... |
| 02.11.2021 | Reference Data（612KB） | Securities Code: 4523
FY 2021 (Ending March 31, 2022)
Second Quarter Financial Results
Reference Dat... | marketscre... |
| 22.09.2021 | Eisai : Latest Value Creation Report (Former Integrated Repo... | Eisai Value Creation Report 2021
Eisai Co., Ltd.
Materiality
Eisai's corporate philosophy is to give... | marketscre... |
| 05.08.2021 | EISAI : RECEIVES AWARD FOR EXCELLENCE IN CORPORATE COMMUNICA... | For Print
August 5, 2021
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') announced ... | marketscre... |
| 05.08.2021 | Altoida Awarded FDA Breakthrough Designation for Development... | Logo “This significant milestone enables Altoida to pioneer a new generation of precision neurology ... | prweb.com/... |
| 30.07.2021 | Eisai : LATE-BREAKING AAIC PRESENTATION EXPLORES POTENTIAL C... | For Print
July 30, 2021
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') and Biogen ... | marketscre... |
| 30.07.2021 | Eisai : and Biogen Present Preliminary Assessment of the Cli... | TOKYO, Jul 30, 2021 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. today announced results of ... | marketscre... |
| 30.07.2021 | Biogen : Late-Breaking AAIC Presentation Explores Potential ... | Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following
18 Mo... | marketscre... |
| 29.07.2021 | Biogen : Late-Breaking AAIC Presentation Explores Potential ... | TOKYO, July 29, 2021 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "E... | marketscre... |
| 08.06.2021 | EISAI CO., LTD.
Eisai: New Data on LENVIMA (lenvatinib) Plu... | TOKYO and KENILWORTH, N.J., Jun 8, 2021 - (JCN Newswire) - - Eisai Co., Ltd. and Merck & Co., In... | marketscre... |
| 31.05.2021 | EISAI CO., LTD.
Eisai : and ITO EN Enter Into Business Alli... | Eisai Co., Ltd. (Headquarters: Tokyo, CEO:
Haruo Naito, 'Eisai') and ITO EN, LTD. (Headquarters: Tok... | marketscre... |
| 01.04.2021 | Digital therapeutics startup Dthera Sciences was sunk by Alz... | (Photo by Sebastian Kaulitzki/Getty Images) | mobihealth... |
| 01.12.2020 | Eisai and Wren Therapeutics enter into research collaboratio... | Eisai and Wren Therapeutics enter into research collaboration agreement for drug discovery for synuc... | cambridgen... |
| 27.11.2020 | EISAI CO., LTD.
Eisai : AbbVie and Eisai Announce an approv... | TOKYO, Nov 27, 2020 - (JCN Newswire) - - AbbVie GK and Eisai Co., Ltd. today announced an approval o... | marketscre... |
| 27.11.2020 | Eisai : AbbVie and Eisai Announce an approval for additional... | TOKYO, Nov 27, 2020 - (JCN Newswire) - - AbbVie GK and Eisai Co., Ltd. today announced an approval o... | marketscre... |
| 25.10.2020 | Eisai and Cogstate Expand Agreement for Global Development a... | | prnewswire... |
| 09.03.2020 | Numab Therapeutics raises CHF 22M series B round | Numab Therapeutics is an oncology-focused biopharmaceutical company developing a pipeline of multi-s... | startuptic... |
| 09.03.2020 | Numab Therapeutics raises CHF 22M series B round | | startuptic... |
| 12.11.2019 | Eisai Launches First Amazon Alexa Skill to Bring Solace &... | – Eisai Inc. launches Ella the Jellyfish, the first Amazon Alexa skill designed for those affected b... | hitconsult... |
| 01.10.2019 | Eisai teams up with Numab to generate cancer therapeutics | | startuptic... |
| 25.04.2019 | Biogen has seen $19 billion wiped out since a promising drug... | Glassdoor/Biogen
The biotech Biogen is based in Cambridge, Massachusetts.
Advertisement
The biotech ... | businessin... |
| 22.03.2019 | Defying analyst expectations, Eisai launches study of a-beta... | Markets in Japan were closed Thursday for the spring equinox, but shares of Eisai were trading Frida... | medcitynew... |
| 22.03.2019 | RIP amyloid beta theory? Nope. Biogen partner launche... | A day after Biogen rattled the biopharma world with the news that its lead late-stage therapy... | endpts.com... |
| 25.10.2018 | Biogen, Eisai fight back against accusations their big ... | After getting slapped hard by critics for the way it handled their recent trial summary for ... | endpts.com... |
| 23.03.2018 | Helsinn buys global rights for skin cancer drug from Acte... | → Swiss pharma group Helsinn is acquiring rights to skin cancer drug Valchlor (marketed as Led... | endpts.com... |
| 09.08.2016 | FDA clears a Phase III path for Biogen’s BACE drug for Alzh... | Biogen has taken another step forward in prepping a Phase III program for its BACE drug for A... | endpts.com... |
| 19.02.2016 | Eisai and PIQUR sign landmark collaboration agreement | | startuptic... |
| 27.06.2012 | Does FDA’s approval of first obesity drug in 13 years reflec... | The U.S. Food and Drug Administration’s move to approve the first obesity drug in 13 years seems to ... | medcitynew... |
| 01.05.2012 | Horizon Discovery and H3 Biomedicine collaborate to validate... | Horizon Discovery and H3 Biomedicine collaborate to validate novel cancer targets
01-05-2012
H3 Biom... | cambridgen... |
| 16.04.2012 | Alzheimer’s researchers form company, look to clinical trial... | ReXceptor is looking to raise funding for a phase 1 clinical trial and will eventually need to contr... | medcitynew... |
| 09.02.2012 | CWRU researchers: Drug shows promise in reducing Alzheimer’s... | Case touted the research as “a dramatic breakthrough in [the] effort to find a cure for Alzheimer’s ... | medcitynew... |
| 02.06.2011 | Alzheimer’s disease drug Aricept faces rising tide of generi... | Aricept’s patents expired last November and the first drugs company to market an Aricept generic was... | medcitynew... |
| 27.04.2011 | FDA clears Biomet’s hip implant | Regulatory roundup | Biomet Inc. received FDA 510(k) clearance for its new hip replacement device.
Warsaw, Ind.-based com... | massdevice... |
| 02.02.2011 | Ultrasound firm considering Research Triangle Park HQ to cou... | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Healt... | medcitynew... |
